Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
Related Questions
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
Do you offer neoadjuvant chemotherapy to nested variant urothelial carcinoma (NVUC) of the bladder?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?
Is there a role for single agent immunotherapy in a patient with T2 muscle-invasive bladder cancer without lymph nodes or distant metastasis who declines chemotherapy and cystectomy?
Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?